ESH MM 2018 | UK NCRI AML17 trial update: everolimus addition for consolidation
Robert Hills of the University of Oxford, Oxford, UK, gives us an update on the addition of the mTOR inhibitor everolimus to consolidation therapy in the UK NCRI AML17 trial (ISRCTN55675535). Prof. Hills describes the results so far, which while not favourable for this specific combination do not rule it out as an effective option in other settings. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
Get great new content delivered to your inboxSign up